leisure time -WSS

leisure time

author：entertainment 2025-09-27 15:20:55 - browse：45

Adam's take main illustration — Molly Ferguson/STAT

The approval Friday of Bluebird Bio’s gene therapy for sickle cell disease should have been a momentum-swinging achievement for the long-struggling biotech. Instead, the company mispriced its new drug and fumbled a pivotal financial lifeline.

The consequences of these strategic blunders — arguably, self-inflicted — could imperil Bluebird’s independence, perhaps even its survival.

Bluebird priced Lyfgenia at $3.1 million, while Vertex Pharmaceutical set the cost of Casgevy, its competing sickle cell treatment also approved on Friday, at $2.2 million. Not only is Lyfgenia significantly more expensive, but its prescribing label carries a “black box” safety warning, which requires patients undergo regular blood monitoring for cancer risk. Casgevy has no similar monitoring requirement.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hollywood unions extend contract negotiations for actors
Next article： The woman behind the Dana Farber

hotspot

WSS

After sickle

Despite FDA approval for Lyfgenia, Bluebird faces stiff competition

Chemotherapy shortages won’t get better under Biden’s latest plan

Radiology is caught between AI's potential and concern for patients

Sanofi says it has 12 blockbusters on the way. Will investors believe it?

What causes an itch? Researchers may have solved the mystery

knowledge

leisure time

explore

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

After sickle

At least 13 dead in Texas as scorching temps continue

In diabetes hearing, Sanders takes on a new foe: food makers

Virginia high school admissions case could be legal follow

Despite FDA approval for Lyfgenia, Bluebird faces stiff competition

In age of alternative facts, a scholarly course on calling out crap

Pharma patents targeted by Biden in move to slash drug prices

Wildfire smoke exposes gaps in outdoor worker protections

Congenital heart disease patients face new threat of heart failure

focus

Radiology is caught between AI's potential and concern for patients

Congenital heart disease patients face new threat of heart failure

What PEPFAR has meant on the ground in Ukraine

FDA needs staff influx to meet gene therapy needs, Marks says

STAT letters to the editor on burnt

Pregnancy discrimination could be enabled by AI

knowledge

hotspot

knowledge

hotspot